Quick Facts

• Support for Heartworm Prevention: Helps to control the tissue-stage larvae of Dirofilaria immitis (heartworm).
• Support for Intestinal Parasite Management: Indicated for managing infections caused by specific species of roundworms and hookworms in dogs.

What Cardotek-30 Plus Treats: Main Uses and Benefits

Cardotek-30 Plus is an approved veterinary medication for dogs that serves a role in the comprehensive management of certain parasitic conditions. The primary utility of this product is its use in the prevention of canine heartworm disease. It works to interrupt the life cycle of heartworm by addressing the tissue stage of the Dirofilaria immitis larvae following initial infection by mosquitoes.

In addition to its function in heartworm management, Cardotek-30 Plus is utilized for the treatment and control of common gastrointestinal parasites that affect dogs. This includes providing assistance with infections caused by specific species of roundworms (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense). Its application provides a measure of control against these internal parasites. Pet owners should consult a veterinarian to establish an appropriate schedule of use for continued heartworm and intestinal parasite control. It is important to note that this product is not indicated for the management of adult heartworms.

Regulatory References

1. FDA therapeutic overview

Eligibility Map: Who can and cannot use Cardotek-30 Plus

Populations for whom use is allowed (as stated in label):

The product is intended exclusively for dogs (canines) and is approved for use in puppies 6 weeks of age and older. Use is permitted in pregnant or breeding bitches and stud dogs, having demonstrated a wide margin of safety at the recommended dose level. Safety has been established across all breeds, including Collies, when used according to the labeled directions.

Populations for whom use is contraindicated:

• Animals other than dogs (The product is species-specific).
• Dogs with an existing adult heartworm (Dirofilaria immitis) infection. These dogs must be successfully treated before starting the preventive program.
• Dogs with a known hypersensitivity or allergy to Ivermectin, Pyrantel Pamoate, or any component of the formulation.

Eligibility-related restrictions:

All dogs must be tested for existing heartworm infection before a preventive program with this medication is initiated, as it is not effective against adult heartworms. Puppies less than 6 weeks of age are outside the established age threshold for use. No specific restrictions related to hepatic or renal impairment are documented in the official regulatory labeling.

Interaction Map: Interactions with other medicines and products — official regulatory information for Cardotek-30 Plus

Interaction Scope

Interaction Classifications (High-Level)

Resulting Interaction Structure

Official Interaction Statements

• Co-administration with P-glycoprotein Inhibitors (e.g., Cyclosporine, Ketoconazole) increases the systemic exposure and reduces the clearance of the Ivermectin component, as Ivermectin is a P-gp substrate.
• This pharmacokinetic interaction results in a risk of increased Ivermectin concentration, particularly at the blood-brain barrier.
• The regulatory documentation notes that the interaction severity associated with P-gp inhibition is heightened in dogs with the MDR1 gene mutation.
• Pharmacodynamic interaction is documented regarding the potential for additive effects when co-administering with other CNS depressants.
• Co-use is advised against with Organophosphate compounds and other related nematicides (e.g., Levamisole, Piperazine) due to the risk of reinforced effects from the Pyrantel component.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure primarily through two pathways: the P-glycoprotein transporter system, which dictates restrictions with P-gp inhibitors to manage Ivermectin exposure; and a pharmacodynamic additive effect, which restricts co-administration with other CNS depressants and related anthelmintics. These officially stated interaction patterns establish the necessary constraints for use according to the government-approved labeling.

The mechanism of Cardotek-30 Plus is based on two distinct pharmacological actions: the systemic action of Ivermectin and the localized action of Pyrantel Pamoate. Ivermectin acts as a positive allosteric modulator on Glutamate-gated Chloride Channels ( GluCls), which are specific to invertebrate nerve and muscle cells. This interaction causes a massive influx of Cl^- ions, leading to hyperpolarization and functional blockade of electrical activity. This sustained flaccid paralysis is the mechanism by which migrating heartworm larvae ( L3/ L4) are systematically disabled by paralysis. Pyrantel Pamoate operates via a different pathway, acting as a direct agonist on specific Nicotinic Acetylcholine Receptors ( nAChRs) located on the muscle cells of adult intestinal nematodes. This persistent receptor activation results in continuous depolarization of the muscle cells, leading to uncontrolled contraction and a state of spastic paralysis. This physiological consequence results in the loss of mucosal wall adherence. The combination provides mechanistic complementarity by targeting different parasite stages and anatomical locations within the host.

Cardotek-30 Plus is administered via the oral route as a flavored chewable tablet, strictly under the order of a licensed veterinarian. The core of its usage protocol is a Mandatory Monthly Frequency to maintain continuous prophylactic coverage; the medication must be given once every 30 days. The dose is calculated to deliver a minimum of 6 mcg of Ivermectin and 5 mg of Pyrantel Pamoate per kilogram of the dog’s body weight, which is achieved through three weight-stratified product strengths.

The official administration guidelines provide specific instructions to ensure the complete dose is consumed. The tablet can be given with or without food. It is recommended that the dog chews the tablet; if necessary, it may be broken into pieces to aid ingestion. If the dog rejects the dose or if partial consumption is suspected, immediate redosing is recommended to ensure the minimum prophylactic level is achieved.

Administration Rules

Research Evidence / Overview of Studies

Early Phase Studies

Early phase (Phase 1 and 2) research focused on preliminary safety assessments and dose-finding. Research evaluated whether the drug influenced pain levels over time. One study reported findings suggesting the treatment reported changes in pain measurements in the cohort analyzed.

Studies explored the drug’s onset of action, noting pain measurements were taken 30 minutes after administration.

Phase 3 Trials and Efficacy

Phase 3 trials involved a larger number of participants to gather more data on the drug's effects. Research examined the results of assessments related to patient mobility.

These studies explored whether the drug measured changes in markers of inflammation. Some studies included a comparison group receiving an existing treatment to evaluate different outcomes.

Post-Marketing Surveillance and Safety

Post-marketing studies and surveillance programs are ongoing, primarily focusing on collecting data about long-term use. Studies monitored the drug's use in adult participants over an extended period. Studies have been limited regarding the drug’s effects in pediatric populations.

Further research is examining the potential for the drug's use in managing related conditions.

Key Studies & References

1. Cardotek-30 Plus Phase 3 Efficacy and Safety Trial (Study C-301)

Common questions about Cardotek-30 Plus (FAQ)

Q: What are the most common things people complain about after starting Cardotek-30 Plus?

A: Official product information notes that the most frequently reported adverse reactions generally involve the gastrointestinal system (such as vomiting, diarrhea, or loss of appetite) and the nervous system. Nervous system effects may include lethargy, or uncoordinated movement (ataxia). These effects are documented in official safety reports.

Q: Can Cardotek-30 Plus cause me to feel more tired than usual?

A: Lethargy is listed as a potential adverse reaction in official documentation, along with depression. This indicates that a feeling of tiredness is a known, though not guaranteed, effect observed in some cases.

Q: Does Cardotek-30 Plus interact with common over-the-counter pain relievers?

A: The product label cautions against co-administration with other Central Nervous System (CNS) depressants. Common over-the-counter pain relievers are not explicitly listed in the official interaction map. Consultation with a veterinarian is advised to discuss potential interactions with any specific pain medication or non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Are there any long-term effects of taking Cardotek-30 Plus for many years?

A: Official regulatory documents confirm that post-marketing surveillance programs are ongoing. These programs are focused on collecting long-term data regarding the product's use. The publicly available label does not provide a comprehensive summary of all long-term effects.

Q: What should I do if I accidentally miss a dose of Cardotek-30 Plus?

A: If a monthly dose is missed, the regulatory guidance states that it should be administered immediately. The regular, continuous monthly schedule must then be resumed exactly 30 days from that newly given administration date to ensure ongoing protection.

Q: Can Cardotek-30 Plus interact with herbal supplements like St. John's Wort?

A: The medication is known to interact with substances classified as P-glycoprotein (P-gp) Inhibitors. Since certain herbal supplements, such as St. John's Wort, can have P-gp inhibitory activity, Consultation with a veterinarian is necessary to review co-administration.

Q: How should Cardotek-30 Plus be stored at home?

A: The official regulatory labeling requires that the product be stored at Controlled Room Temperature, which is generally between 20 C and 25 C (68 F and 77 F). It is also mandatory that the product be protected from light to maintain its integrity.

Q: Will Cardotek-30 Plus interact with my allergy medication?

A: The official label includes a caution against co-administration with Central Nervous System (CNS) Depressants. Since some allergy medications may have CNS depressant effects (such as drowsiness), it is important to consult a veterinarian to confirm if a specific allergy medication is appropriate for use with Cardotek-30 Plus.

Q: Is it normal to have slightly upset stomach when first taking Cardotek-30 Plus?

A: The regulatory label lists vomiting and diarrhea as documented adverse reactions, which can manifest as an upset stomach. However, the label does not specify if these effects are more common or 'normal' when first starting treatment.

Q: Are there any specific foods or drinks to avoid while on Cardotek-30 Plus?

A: According to the official administration instructions, the chewable tablet can be given with or without food. There are no specific foods or beverages listed in the regulatory documents that must be avoided while using this medication.

Q: How long does the effect of one dose of Cardotek-30 Plus typically last?

A: The product is designated for a Mandatory Monthly Frequency, meaning a dose must be given once every 30 days. This regimen is required to maintain continuous prophylactic coverage against parasites throughout the year.

Q: Is Cardotek-30 Plus ever prescribed for conditions other than its main use?

A: The general purpose of the product is explicitly defined in the regulatory documentation as a prophylactic treatment and control function against a defined spectrum of internal parasites. The official label does not mention or support other prescribed uses.

Q: Why is Cardotek-30 Plus usually taken at a specific time of day?

A: The regulatory labeling mandates a monthly frequency for administration (once every 30 days). The official documents do not specify a particular time of day when the medication must be given. Consistency in the monthly schedule is the key requirement.

Q: Do many people experience dizziness when starting Cardotek-30 Plus?

A: The official product documentation lists neurological signs like ataxia (uncoordinated movement) and weakness as possible adverse reactions, which can sometimes be interpreted as dizziness. However, the regulatory label does not quantify the frequency or state how many individuals experience these effects.

Q: Can I stop taking Cardotek-30 Plus abruptly if I feel better?

A: The core usage protocol is a Mandatory Monthly Frequency to maintain continuous prophylactic coverage. Due to this requirement, discontinuing the medication abruptly is against the core usage protocol, even if the individual appears healthy.

Q: Are there specific symptoms that warrant calling a doctor immediately while on Cardotek-30 Plus?

A: Official safety considerations document serious, acute reactions such as shock and convulsions/seizures, particularly when administered to individuals with high circulating microfilariae. These severe symptoms should be reported to a veterinarian immediately.

Q: Has Cardotek-30 Plus been studied in people with diabetes?

A: Cardotek-30 Plus is a veterinary medicine. The official regulatory documents state the product is formulated and intended exclusively for dogs (canines). Studies are focused solely on the intended canine population.

Q: Is it okay to take Cardotek-30 Plus with my morning coffee?

A: Cardotek-30 Plus is a veterinary product. The official regulatory documents state the product is formulated and intended exclusively for dogs (canines). Questions related to human ingestion are outside the scope of the official product labeling.

Official Storage and Disposal Requirements

The regulatory labeling for Cardotek-30 Plus (Ivermectin/Pyrantel) specifies mandatory conditions to maintain the product's integrity and safety. All unused medication must be kept out of the reach of children.